Fredun Pharmaceuticals (BOM:539730) Total Liabilities : ₹1,861 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Fredun Pharmaceuticals Total Liabilities?

Fredun Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was ₹1,861 Mil.

Fredun Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 (₹1,671.45 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹1,861.28 Mil).

Fredun Pharmaceuticals's annual Total Liabilities increased from Mar. 2022 (₹1,189.28 Mil) to Mar. 2023 (₹1,609.04 Mil) and increased from Mar. 2023 (₹1,609.04 Mil) to Mar. 2024 (₹1,861.28 Mil).

Fredun Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Fredun Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fredun Pharmaceuticals Total Liabilities Chart

Fredun Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

1,000.57

1,185.48

1,189.28

1,609.04

1,861.28

Fredun Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,609.04	-	1,671.45	-	1,861.28

Fredun Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Fredun Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1668.275	+	(127.981	+	41.365
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	23.658)
	=	1,861

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	3075.991	-	1214.712
	=	1,861

Fredun Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1668.275	+	(127.981	+	41.365
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	23.658)
	=	1,861

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3075.991	-	1214.712
	=	1,861

Fredun Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Fredun Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Fredun Pharmaceuticals (BOM:539730) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fredun Pharmaceuticals Ltd (BOM:539730) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Ganpatrao Kadam Marg, 11th Floor, Urmi Estate, Lower Parel (West), Mumbai, MH, IND, 400013

Website

http://www.fredungroup.com

Fredun Pharmaceuticals Ltd is an India based company engaged in the business of pharmaceuticals and healthcare. The company manufactures pharmaceutical formulations, nutraceuticals, herbal supplements, and dietary supplements. In addition, it also manufactures animal healthcare products through its group companies. It sells its products in India and also exports its formulations as branded generics to international countries.

Fredun Pharmaceuticals (BOM:539730) Headlines

No Headlines